Abstract:P53 overexpression plays a critical role in cancer pathogenesis by disrupting the intricate regulation of cellular proliferation. Despite its firmly established function as a tumor suppressor, elevated p53 levels can paradoxically contribute to tumorigenesis, influenced by factors such as exposure to carcinogens, genetic mutations, and viral infections. This phenomenon is observed across a spectrum of cancer types, including bladder (BLCA), ovarian (OV), cervical (CESC), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), diffuse large B-cell lymphoma (DLBC), esophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and uterine corpus endometrial carcinoma (UCEC). This broad spectrum of cancers is often associated with increased aggressiveness and recurrence risk. Effective therapeutic strategies targeting tumors with p53 overexpression require a comprehensive approach, integrating targeted interventions aimed at the p53 gene with conventional modalities such as chemotherapy, radiation therapy, and targeted drugs. In this extensive study, we present a detailed analysis shedding light on the multifaceted role of TP53 across various cancers, with a specific emphasis on its impact on disease-free survival (DFS). Leveraging data from the TCGA database and the GTEx dataset, along with GEPIA, UALCAN, and STRING, we identify TP53 overexpression as a significant prognostic indicator, notably pronounced in prostate adenocarcinoma (PRAD). Supported by compelling statistical significance (p < 0.05), our analysis reveals the distinct influence of TP53 overexpression on DFS outcomes in PRAD. Additionally, graphical representations of overall survival (OS) underscore the notable disparity in OS duration between tumors exhibiting elevated TP53 expression (depicted by the red line) and those with lower TP53 levels (indicated by the blue line). The hazard ratio (HR) further emphasizes the profound impact of TP53 on overall survival. Moreover, our investigation delves into the intricate TP53 protein network, unveiling genes exhibiting robust positive correlations with TP53 expression across 13 out of 27 cancers. Remarkably, negative correlations emerge with pivotal tumor suppressor genes. This network analysis elucidates critical proteins, including SIRT1, CBP, p300, ATM, DAXX, HSP 90-alpha, Mdm2, RPA70, 14-3-3 protein sigma, p53, and ASPP2, pivotal in regulating cell cycle dynamics, DNA damage response, and transcriptional regulation. Our study underscores the paramount importance of deciphering TP53 dynamics in cancer, providing invaluable insights into tumor behavior, disease-free survival, and potential therapeutic avenues.

Dysfunction of the TP53 in some lymphoid malignancies and blood cancer

p53 tumor suppressor and iron homeostasis.

Functional Diversity of P53 in Human and Wild Animals

Prognostic Significance of the Tumor Suppressor Protein P53 Gene in Childhood Acute Lymphoblastic Leukemia.

TP53: the unluckiest of genes?

p53 signaling in cancer progression and therapy

Comprehensive Bioinformatic Investigation of TP53 Dysregulation in Diverse Cancer Landscapes

Targeting p53 pathways: mechanisms, structures, and advances in therapy

A Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development

Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53

Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant

Mutant p53 in cancer therapy-the barrier or the path.

TP53 in MDS and AML: Biological and Clinical Advances.

P53 Mutation and Deletion Contribute to Tumor Immune Evasion

Mutant p53 in Cancer Progression and Targeted Therapies

TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)

Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe

Role of p53 in regulation of hematopoiesis in health and disease

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation